Volunteer Research Group — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$6,523	1
2023	Research	$11,827	1
2021	Research	$0	1
2020	Research	$7,824	2
2019	Research	$43,075	2

Breakdown

Who paid Research payments · program years 2019–2024

Novartis Pharmaceuticals Corporation $64,252 4 payments
Eli Lilly and Company $4,997 2 payments
Merck Sharp & Dohme Corporation $0 1 payment

Studies the money was for Research payments · program years 2019–2024

A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $45,902 2 payments
An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $18,350 2 payments
An Open Label, Long Term, Safety Study of Lasmiditan 100 MG and 200 MG in the Acute Treatment of Migraine Gladiator $4,997 2 payments
A Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK-8342B etonogestrel 17 -estradiol vaginal ring in healthy women 18 years of age and older, at risk for pregnancy $0 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.